PracticeUpdate: Haematology & Oncology

I have high grade serous ovarian cancer TEST ME

for BRCAm If I am positive

TREAT ME

with Lynparza TM *

*as maintenance therapy for PSR disease, in response after platinum-based chemotherapy (must have ≥ 2 courses) 1

PBS Information: This product is not listed on the PBS

BEFORE PRESCRIBING, PLEASE REVIEW FULL PRODUCT INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR www.astrazeneca.com.au/PI LYNPARZA ® (olaparib) Minimum Product Information: INDICATIONS: Monotherapy for the maintenance treatment of patients with platinum- sensitive relapsed BRCA -mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum- based chemotherapy. Prior treatment must have included at least 2 courses of platinum- based regimens. CONTRAINDICATIONS: Hypersensitivity to the active substance (olaparib) or to any of the excipients. PRECAUTIONS: Haematological toxicity is common in patients treated with olaparib and usually mild -moderate. Patients should not start treatment with LYNPARZA until they have recovered from haematological toxicity caused by previous anti - cancer therapy. A baseline complete blood count followed by monthly monitoring is recommended for the first 12 months of treatment and periodically after this. Myelodysplastic syndrome/Acute Myeloid Leukaemia (MDS/AML) have been reported in a small number of patients (<1%) and the majority of reports have been fatal. Pneumonitis has been reported in a small number of patients receiving olaparib, and some reports have been fatal. Use in pregnancy: Category D. LYNPARZA may cause foetal harm when administered to a pregnant woman. Women of child bearing potential must use effective contraception during treatment and for 1 month after receiving the last dose. Use during lactation: Breast feeding should be avoided in women receiving LYNPARZA and for 1 month after the last dose. Use in Men: Not indicated Children or adolescents: Not indicated. Interactions with other medicines. INTERACTIONS: LYNPARZA co administration with strong CYP3A inducers or inhibitors should be avoided. Addition of LYNPARZA and cytotoxic agents has been shown to potentiate and prolong myelosuppressive side effects. ADVERSE REACTIONS : Very common (≥10%): decreased appetite, headache, dysgeusia, dizziness, nausea, vomiting, diarrhoea, dyspepsia, fatigue, anaemia, neutropenia, lymphopenia, mean corpuscular volume elevation, increased creatinine; Common (≥1% to <10%): stomatitis, upper abdominal pain, thromboyctopenia; for other listed adverse reactions, see full PI. DOSAGE AND ADMINISTRATION: 400 mg (eight 50 mg capsules) taken twice daily, equivalent to a total daily dose of 800 mg. LYNPARZA should be taken on an empty stomach and patients should refrain from eating

for 2 hours. Date of first inclusion in the ARTG: 7th January 2016 Reference 1. Lynparza Approved Product Information 10 October 2016.

Lynparza TM is a trademark of the AstraZeneca group of companies. AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. AstraZeneca Medical Information: 1800 805 342. www.astrazeneca.com.au. WL293061. AU-1404. Date of preparation November 2016.